



# Updates in Management of Unresectable Locally Advanced NSCLC

#### Ana I. Velazquez, MD MSc University of California, San Francisco USA





#### DISCLOSURES

Company	Relationship(s)
Astra Zeneca	Consultant
Corbus Pharmaceuticals	Stock



Locally Advanced NSCLC

- 20% of NSCLC at diagnosis
- Heterogeneous group
- Treatment consists of multimodality therapy and is influenced by potential of surgical resection



#### 8th Edition AJCC/UICC Stage


т/м	Subgroup	NO	N1	N2	N3
T1	T1a T1b T1c	IA1 IA2 IA3	IIB IIB IIB	IIIA IIIA IIIA	IIIB IIIB IIIB
T2	T2a	IB	IIB	IIIA	IIIB
	T2b	IIA	IIB	IIIA	IIIB
Т3	Т3	IIB	IIIA	IIIB	IIIC
T4	T4	IIIA	IIIA	IIIB	IIIC
M1	M1a M1b	IVA IVA	IVA IVA	IVA IVA	IVA IVA
	M1c	IVB	IVB	IVB	IVB





#### **Current Standard of Care: PACIFIC**

 In February 2018, FDA approved durvalumab for treatment of unresectable stage III NSCLC without disease progression following concurrent CRT.



\*RT dosage typically 60 to 66 Gy in 30 to 33 fractions. <sup>†</sup>Using the Ventana SP263 IHC assay. <sup>‡</sup>PFS defined as time from randomization to the date of objective disease progression or death by any cause in the absence of progression.






Median OS, mo

Median PFS, mo

#### **PACIFIC: 5-year outcomes**





EGFR or ALK aberration status

1%-24% (post hoc analysis)

 $\geq$  1% (post hoc analysis)

< 1% (post hoc analysis)

Positive<sup>d</sup>

Negative

Unknown

Unknown

≥ 25%

< 25%

PD-L1 expression level

#### **PACIFIC: 5-year outcomes**

21/29 (72.4)

169/317 (53.3)

78/130 (60.0)

61/115 (53.0)

105/187 (56.1)

102/174 (58.6)

50/97 (51.5)

111/212 (52.4)

55/90 (61.1)

		No. of Events / No	of Patiente (%)		11	
	Group	Durvalumab	Placebo	-		ratified HR 15% CI)
200	All patients	268/476 (56.3)	175/237 (73.8)			0.48 to 0.70)
nce	Sex					
	Male	192/334 (57.5)	122/166 (73.5)	<b>⊢−●−−</b> 1	0.61 (0	).48 to 0.76)
	Female	76/142 (53.5)	53/71 (74.6)		0.52 (0	.36 to 0.74)
	Age at random assignment					
	< 65 years	140/261 (53.6)	100/130 (76.9)	H <b>O</b> H		).36 to 0.60)
	≥ 65 years	128/215 (59.5)	75/107 (70.1)	<b>⊢</b> ●	0.76 (0	).57 to 1.01)
	Smoking status					
	Smoker	246/433 (56.8)	158/216 (73.1)			).50 to 0.75)
	Nonsmoker	22/43 (51.2)	17/21 (81.0)	<b>←</b> →→	0.33 (0	).17 to 0.63)
	NSCLC disease stage	100/050 (50.4)	05/125 /20 0)		0.52.0	10.4- 0.00)
nes	IIIB	132/252 (52.4) 130/212 (61.3)	95/125 (76.0) 77/107 (72.0)			0.40 to 0.69) 0.48 to 0.85)
163	Tumor histologic type	130/212 (01.3)	///10/ (/2.0)		0.64 (0	1.46 [0 0.65]
	Squamous	138/224 (61.6)	74/102 (72.5)		- 0.71 (0	).54 to 0.94)
	All other	130/252 (51.6)	101/135 (74.8)			).37 to 0.63)
	Best response to prior treatme		101,100 (7110)		0110 (0	
	Complete response	5/9 (55.6)	4/7 (57.1)		Notic	alculated <sup>a</sup>
	Partial response	126/237 (53.2)	85/112 (75.9)	<b>———</b>		).43 to 0.74)
	Stable disease	122/222 (50.6)	04/445 (72.0)		0.57.0	14 to ∩ 76)
11/14/70 0					0.00(0.00+1.071)	
11/14 (78.6)					0.82 (0.39 to 1.71)	1)
124/165 (75.2)	<b>⊢−●−−</b> 1				0.52 (0.41 to 0.65)	3)
40/58 (69.0)					0.74 (0.51 to 1.09)	
40/00 (09.0)					0.74(0.51(0.1.09))	
						0)
33/44 (75.0)					0.44 (0.29 to 0.67)	
						2)
77/105 (73.3)	<b>⊢</b> ●	-			0.64 (0.48 to 0.86)	
65/88 (73.9)					0.60 (0.44 to 0.82)	8)
36/47 (76.6)					0.51 (0.33 to 0.78)	7)
69/91 (75.8)					0.47 (0.35 to 0.64)	3)
41/58 (70.7)					0.80 (0.53 to 1.20)	3)
41/36(70.7)					0.80 (0.53 [0 1.20)	3
	0.2 0.4 0.6 0.	8 1.0 1.1	2 1.4	1.6 1.8		1)
						5)
						9)
	Durvalumab Be	ttor Plac	oho Ro	ttor		7)
			eno pe			6)
						2)
	1%-24% (post hoc analysis)	50/97 (51.5)	36/47 (76.6)	<b>—</b> •—–	0.51 (0	0.33 to 0.78)
	≥ 1% (post hoc analysis)	111/212 (52.4)	69/91 (75.8)	<b>———</b> —————————————————————————————————	0.47 (0	).35 to 0.64)
	< 1% (post hoc analysis)	55/90 (61.1)	41/58 (70.7)		0.80 (0	).53 to 1.20)
				0.2 0.4 0.6 0.8	1.0 1.2 1.4 1.6 1.8	
				<	>	
				Durvalumab Bette	er Placebo Better	
A DESCRIPTION OF THE R. A. A. MILLING						

Spigel DR, et al. JCO. 40, no. 12 : 1301-1311.





## **Unresectable Stage III NSCLC**

• Concurrent CRT with platinum doublet chemotherapy followed by durvalumab for 1 year.

#### **Unanswered questions:**

- How can we improve outcomes? Novel combinations? Concurrent IO + CRT? Dual CPI?
- How does molecular testing affect management?
- How does PD-L1 impact our management?
  - In the US, durvalumab is approved irrespective of PD-L1 expression
  - In the EU, durvalumab is only approved in PD-L1+ population





#### Sugemalimab vs placebo after concurrent or sequential chemoradiotherapy in patients with unresectable stage III NSCLC (GEMSTONE-301): final progression-free survival analysis of a phase 3 study

#### Presenter: Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, China


Yi-Long Wu<sup>1</sup>, Qing Zhou<sup>1</sup>, Ming Chen<sup>2,3</sup>, Ou Jiang<sup>4</sup>, Yi Pan<sup>1</sup>, Desheng Hu<sup>5</sup>, Qin Lin<sup>6</sup>, Gang Wu<sup>7</sup>, Jiuwei Cui<sup>8</sup>, Jianhua Chang<sup>9,10</sup>, Yufeng Cheng<sup>11</sup>, Cheng Huang<sup>12</sup>, Anwen Liu<sup>13</sup>, Nong Yang<sup>14</sup>, Youling Gong<sup>15</sup>, Chuan Zhu<sup>16</sup>, Zhiyong Ma<sup>17</sup>, Jian Fang<sup>18</sup>, Gongyan Chen<sup>19</sup>, Jun Zhao<sup>18</sup>, Anhui Shi<sup>18</sup>, Yingcheng Lin<sup>20</sup>, Guanghui Li<sup>21</sup>, Yunpeng Liu<sup>22</sup>, Dong Wang<sup>23</sup>, Rong Wu<sup>24</sup>, Xinhua Xu<sup>25</sup>, Jianhua Shi<sup>26</sup>, Zhihua Liu<sup>27</sup>, Rumei Chen<sup>28</sup>, Qiang Wang<sup>28</sup>, Mengmeng Qin<sup>28</sup>, Yiding Ma<sup>28</sup>, Jingru Wang<sup>28</sup>, Jason Yang<sup>28</sup>

<sup>1</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China; <sup>3</sup>The Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China; <sup>3</sup>Sun Yat-sen University Cancer Centre, Guangzhou, China; <sup>4</sup>The Second People's Hospital of Neijiang, Neijiang, China; <sup>5</sup>Sub el Cancer Hospital, Wuhan, China; <sup>6</sup>The First Affiliated Hospital of Xiamen University, Xiamen, China; <sup>7</sup> Cancer Centre, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; <sup>8</sup>The First Hospital of Jilin University, Changchun, China; <sup>9</sup>Fudan University Cancer Centre, Shandong University, Jinan, China; <sup>14</sup>Fujian Medical University, Fujian Provincial Cancer Hospital, Fuzhou, China; <sup>15</sup>The Second Affiliated Hospital of Nanchang University, Nanchang, China; <sup>14</sup>Hunan Cancer Hospital, Changsha, China; <sup>14</sup>Ugian Provincial Cancer Hospital, Fuzhou, China; <sup>14</sup>The Second Affiliated Hospital of Nanchang University, Nanchang, China; <sup>14</sup>Hunan Cancer Hospital, Changsha, China; <sup>14</sup>West China Hospital, Tohoging, China; <sup>14</sup>Hunan Cancer Hospital, China; <sup>14</sup>Hunan Cancer Hospital, China; <sup>14</sup>Hunan Cancer Hospital, China; <sup>15</sup>Mest China Hogital of Sichuan University, Chengdu, China; <sup>15</sup>Chongqing University Three Gorges Hospital, Chongqing, China; <sup>14</sup>The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China; <sup>16</sup>Beijing Cancer Hospital, Beijing, China; <sup>13</sup>Harbin Medical University Cancer Hospital, Harbin, China; <sup>14</sup>Cancer Hospital, Cancer Hospital, Cancer Hospital, China; <sup>13</sup>Cancer Hospital of Shantou University Medical College, Shantou, China; <sup>21</sup>Xinqiao Hospital of Army Medical University, Chongqing, China; <sup>23</sup>Army Medical Centre of PLA, Chongqing, China; <sup>25</sup>Shengjing Hospital of China Medical University, Shenyang, China; <sup>23</sup>Army Medical Centre of PLA, Chongqing, China; <sup>25</sup>Chone Pharmaceuticals Suzhou, Shanghai, China



#### **GEMSTONE-301: Study Design**





#### **Statistical Considerations**

- PFS by BICR is tested first at a two-sided alpha of 0.05; if PFS is significant, then OS would be tested at a two-sided alpha of 0.05
- · Final PFS analysis were planned when approximately 262 PFS events occurred
- Interim and final OS analysis were planned when approximately 175 and 260 OS events occurred, respectively

DoR: duration of response; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; PK: pharmacokinetics; Q3W: once every 3 weeks; TTDM: Time to death or distant metastasis

\*At the discretion of the study investigator, patients without progression and with tolerance for Sugemalimab after 24 months of treatment may continue to receive the treatment.






#### **GEMSTONE-301:** Baseline Characteristics

	Sugemalimab (n=255)	Placebo (n=126)
Age, Median (range), years	61.0 (46,78)	60.0 (42,73)
Sex, Male/Female, n (%)	236 (92.5%)/19 (7.5%)	115 (91.3%)/11 (8.7%)
Baseline ECOG PS, 0/1, n (%)	78 (30.6%)/177 (69.4%)	38 (30.2%)/88 (69.8%)
Smoking Status, Never/Former or current, n (%)	42 (16.5%)/213 (83.5%)	16 (12.7%)/110 (87.3%)
Disease Stage <sup>#</sup> , IIIA/IIIB/IIIC, n (%)	74 (29.0%)/146 (57.3%)/33 (12.9%)	32 (25.4%)/65 (51.6%)/28 (22.2%)
Histology Type*, Squamous/Non-squamous, n (%)	177 (69.4%)/76 (29.8%)	89 (70.6%)/37 (29.4%)
CRT Type, sCRT/cCRT, n (%)	86 (33.7%)/169 (66.3%)	41 (32.5%)/85 (67.5%)
Radiotherapy Dose, < 60 Gy/≥ 60 Gy, n (%)	43 (16.9%)/212 (83.1%)	21 (16.7%) /105 (83.3%)
Best Response to CRT, CR/PR/SD, n (%)	4 (1.6%)/172 (67.5%)/79 (31.0%)	2 (1.6%)/77 (61.1%)/47 (37.3%)
Prior Platinum Treatment, Cisplatin/Carboplatin/Nedaplatin, n (%)	130 (51.0%)/82 (32.2%)/56 (22.0%)	61 (48.4%)/47 (37.3%)/20 (15.9%)
Time from Last Radiation to Randomization, $\leq 14 \text{ days}/> 14 \text{ days}$ , n (%)	47 (18.4%)/208 (81.6%)	24 (19.0%)/102 (81.0%)
Time from Last Radiation to Randomization, ≤ 25 days/> 25 days, n (%)	121 (47.5%)/134 (52.5%)	77 (61.1%)/49 (38.9%)



#### **GEMSTONE-301: PFS**










#### **GEMSTONE-301: PFS by CRT Type**




•

- Median follow-up: 30.6 vs 27.8 months ٠
- Median time from start date of CRT to randomization: 156.5 vs 168.0 days
- Median time from start date of CRT to randomization: 72.0 vs 69.0 days



#### **GEMSTONE-301: OS**










#### Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiation for Unresectable Stage IIIA/IIIB NSCLC

Nasser Hanna, MD Indiana University Simon Comprehensive Cancer Center United States



## **Study Design**





- Multi-center, open label randomized phase II trial
- Duration of immunotherapy was <u>6 months</u> in both arms
- Nivolumab arm compared to historical control of CCRT alone
- Nivolumab/Ipilimumab arm compared to

historical control of CCRT -> Durvalumab


	Nivolumab Alone (N=54)	Nivo/Ipi (N=51)
Median Age, yrs (range)	65 (44-82)	63 (41-83)
Gender, n (%)		
Male	24 (44.4)	29 (56.9)
Race, n (%)		
White	2 (77.8)	30 (58.8)
Black/African-American	10 (18.5)	16 (31.4)
Other/Unknown	2 (3.7)	5 (9.8)
ECOG PS, n (%)		
0	18 (33.3)	27 (52.9)
Stage, n (%)		
IIIA	30 (55.6)	29 (56.9)
Histology, n (%)		
Non-Squamous	31 (57.4)	28 (54.9)
Chemotherapy Regimen, n (%)		
Carboplatin/Paclitaxel	36 (66.7)	37 (72.5)
Cisplatin/Pemetrexed	8 (14.8)	3 (5.9)
Cisplatin/Etoposide	7 (13)	7 (13.7)
Carboplatin/Pemetrexed	3 (5.6)	4 (7.8)
Completed 100% of Planned Tx	38 (70.4)	23 (45.1)



#### **Study Population**



#### **Results**





	Nivolumab Alone (N= 52)	Nivolumab/Ipilimumab (N= 47)
Median F/u, months (range)	28.5 (2-44.2)	29.4 (3.2-46.8)
Progression Free Survival*		
18- Month (95% CI)	64.0 (53.8-72.6)	67.7 (57.6-75.9)
P-value	<0.1	<0.1
Median, months (95% CI)	25.8 (23.0-NR)	25.4 (25.0-NR)
Overall Survival		
18- Month (95% CI)	82.8 (69.5-90.7)	85.7 (72.3-92.9)
24- Month (95% CI)	78.2 (63.9-87.3)	80.8 (66.1-89.6)
Median, months (95% CI)	NR (NR-NR)	NR (28.1-NR)



#### **Adverse Events**

	Nivolumab Alone (N=54)	Nivolumab/Ipilimumab (N=51)
Any Treatment-Related AE (TRAE), n (%)	39 (72.2)	41 (80.4)
Any Grade ≥3 AE, n (%)*	21 (38.9)	27 (52.9)
Any Grade ≥3 TRAE, n (%)	10 (18.5)	14 (27.5)
TRAE Occurring in≥10% Pts, n (%)		
Fatigue	17 (31.5)	16 (31.4)
Dyspnea	8 (14.8)	10 (19.6)
Rash	9 (16.7)	8 (15.7)
Hypothyroidism	7 (13)	8 (15.7)
Diarrhea	4 (7.4)	10 (19.6)
Pruritus	5 (9.3)	9 (17.7)
Arthralgia	2 (3.7)	6 (11.8)
Nausea	2 (3.7)	6 (11.8)
Pneumonitis		
Grade ≥2	12 (22.2)	16 (31.4)
Grade 3 (no Gr 4/5 pneumonitis)	5 (9.3)	9 (17.6)
Median time to Gr ≥2 Pneum, mo. (range)	11.9 (4.1-36.6)	7.3 (1.3-36.9)





## Phase II Study of Durvalumab Plus Concurrent Radiotherapy in Unresectable Locally Advanced NSCLC DOLPHIN Study (WJOG11619L)

<u>Motoko Tachihara</u><sup>1</sup>, Kayoko Tsujino<sup>2</sup>, Mototsugu Shimokawa<sup>3</sup>,Takeaki Ishihara<sup>4</sup>, Hidetoshi Hayashi<sup>5</sup>, Yuki Sato<sup>6</sup>, Takayasu Kurata<sup>7</sup>, Shunichi Sugawara<sup>8</sup>, Yoshimasa Shiraishi<sup>9</sup>, Shunsuke Teraoka<sup>10</sup>, Koichi Azuma<sup>11</sup>, Haruko Daga<sup>12</sup>, Masafumi Yamaguchi<sup>13</sup>, Takeshi Kodaira<sup>14</sup>, Miyako Satouchi<sup>15</sup>, Nobuyuki Yamamoto<sup>10</sup>, Kazuhiko Nakagawa<sup>5</sup>

<sup>1</sup>Division of Respiratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. <sup>2</sup>Department of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan.<sup>3</sup>Department of Biostatistics, Yamaguchi University Graduate School of Medicine Yamaguchi, Ube, Japan. <sup>4</sup>Division of Radiation Oncology, Kobe University Graduate School of Medicine, Kobe, Japan. <sup>5</sup>Department of Medical Oncology, Kindai University, Osakasayama, Japan. <sup>6</sup>Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan. <sup>7</sup>Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan. <sup>8</sup>Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. <sup>9</sup>Research Institute for Diseases of the Chest, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.<sup>10</sup>Internal Medicine III, Wakayama Medical University, Wakayama, Japan.<sup>11</sup>Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.<sup>14</sup>Departments of Rediation Oncology, Aichi Cancer Center, Hospital, Osaka, Japan.<sup>14</sup>Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi.<sup>15</sup>Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.




# DOLPHIN: Study Design



 $\alpha$ =0.05(one-sided) and power 0.8

Multi-center, Single arm, Investigator Initiated, phase II trial (JapicCTI-194840)



**Primary endpoint**:12-month PFS rate (assessed by independent central review) **Secondary endpoints**:PFS, OS, objective response rate, disease control rate, treatment completion rate, time to death or distant metastasis, and safety




## **DOLPHIN: PFS by ICR**

Character	n=35	
Age		72( 44-83)
Sex	male(%)	31 (88.6)
Smoking history	never	1 (2.9)
	former	16 (45.7)
	current	18 (51.4)
Pathology	adenocarcinoma	19 (54.3)
	Squamous cell carcinoma	15 (42.9)
	NOS	1 (2.9)
Stage	post-operative recurrence	9 (25.7)
	IIIA	16 (45.7)
	IIIB	7 (20.0)
	IIIC	3 (8.6)
ECOG PS	0/1	19/16 (54.3/45.7)
TPS (SP263)		60(1-100)
Radiation	3D-CRT	24 (70.6)



#### 12-month PFS rate by ICR






#### DOLPHIN: Response Rate by ICR Safety

	n(%)
Any grade AEs	34 (100)
Grade 3/4	16 (47.1)
Grade 5	2 (5.9)
Leading to discontinuation of durvalumab	6 (17.6)
Leading to discontinuation of RT	0 (0.0)
Any grade treatment-related AEs	30 (88.2)
SAEs	13 (38.2)
Severe immune-mediated AEs	10 (29.4)

Pneumonitis or Radiation Pneumonitis	n(%)
Any grade	21 (61.8)
Grade 3/4	4 (11.8)
Grade 5	0 (0.0)
Leading to discontinuation of durvalumab	2 (5.9)
Leading to discontinuation of RT	0 (0.0)







## **Take Home Points:**

- Multidisciplinary discussion is key
- Obtain molecular testing in ALL NSCLC
- Unresectable NSCLC without actionable mutations: PACIFIC remains standard
  - Concurrent CRT with platinum doublet chemotherapy  $\rightarrow$  durvalumab for 1 yr.
- Addition of Ipilimumab -> increase % pneumonitis



### **Remaining Questions:**

- How can we improve outcomes?
  - Novel combinations?
  - Concurrent IO + CRT?
  - -Induction (chemo)-immunotherapy?
- Role of durvalumab in patients with PD-L1 negative tumors?
- Length of consolidation immunotherapy?
- Can we de-escalate chemotherapy in unresectable disease?
- Role of targeted therapies in unresectable NSCLC with oncogenic alterations?
  - Role of EGFR TKIs in the post-ADAURA era?







# Thank you!

## Questions?